1. Home
  2. RQI vs NUVB Comparison

RQI vs NUVB Comparison

Compare RQI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Quality Income Realty Fund Inc

RQI

Cohen & Steers Quality Income Realty Fund Inc

N/A

Current Price

$12.65

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

NUVB

Nuvation Bio Inc.

N/A

Current Price

$4.70

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RQI
NUVB
Founded
2002
2018
Country
United States
United States
Employees
N/A
291
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RQI
NUVB
Price
$12.65
$4.70
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$11.22
AVG Volume (30 Days)
484.2K
4.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$182.76
Revenue Next Year
N/A
$91.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.39
$1.57
52 Week High
$13.39
$9.75

Technical Indicators

Market Signals
Indicator
RQI
NUVB
Relative Strength Index (RSI) 44.66 35.60
Support Level $12.14 $3.18
Resistance Level $13.38 $5.73
Average True Range (ATR) 0.19 0.34
MACD -0.08 -0.06
Stochastic Oscillator 22.83 29.62

Price Performance

Historical Comparison
RQI
NUVB

About RQI Cohen & Steers Quality Income Realty Fund Inc

COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: